More about

Metabolic Dysfunction-Associated Steatotic Liver Disease

News
June 13, 2024
2 min read
Save

Hot flash severity may predict metabolic-associated liver disease

Hot flash severity may predict metabolic-associated liver disease

BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.

News
June 07, 2024
2 min read
Save

Denifanstat achieves ‘statistically significant’ improvements in liver histology in MASH

Denifanstat achieves ‘statistically significant’ improvements in liver histology in MASH

Denifanstat, a fatty acid synthase inhibitor, outperformed placebo in metabolic dysfunction-associated steatohepatitis resolution without worsening of fibrosis and fibrosis improvement, according to data presented at EASL Congress.

News
May 24, 2024
2 min read
Save

Survodutide upholds ‘promising’ reduced liver fat, fibrosis biomarkers in MASH at 28 weeks

Survodutide upholds ‘promising’ reduced liver fat, fibrosis biomarkers in MASH at 28 weeks

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

News
May 22, 2024
2 min read
Save

Prevalence of advanced fibrosis similar in lean, non-lean MASLD, linked to genetic risk

Prevalence of advanced fibrosis similar in lean, non-lean MASLD, linked to genetic risk

WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic dysfunction-associated steatotic liver disease and may be associated with genetic risk, according to data at Digestive Disease Week.

News
May 20, 2024
2 min read
Save

Parental obesity linked to up to 55% increased risk for MASLD among adult offspring

Parental obesity linked to up to 55% increased risk for MASLD among adult offspring

WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.

News
May 20, 2024
1 min read
Save

Bariatric surgery associated with lower mortality, health care cost in patients with MASLD

Bariatric surgery associated with lower mortality, health care cost in patients with MASLD

WASHINGTON — Bariatric surgery was associated with improved clinical outcomes and more cost-effective health care resource utilization among patients with metabolic dysfunction-associated steatotic liver disease, according to data.

News
May 20, 2024
2 min read
Save

‘Encouraging’ data: GLP-1RAs linked to lower risk for cirrhosis in MASLD, type 2 diabetes

‘Encouraging’ data: GLP-1RAs linked to lower risk for cirrhosis in MASLD, type 2 diabetes

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

News
May 13, 2024
2 min read
Save

Playing sports may lower insulin resistance, reduce odds for MASLD in type 1 diabetes

Playing sports may lower insulin resistance, reduce odds for MASLD in type 1 diabetes

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.

CME
Article

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis
0.75 CME
0.75 ANCC
45 MINS
$0 FEE
News
April 30, 2024
2 min read
Save

Honoring Stephen A. Harrison, MD, FAASLD: Pioneer who ‘propelled field of MASH forward’

Honoring Stephen A. Harrison, MD, FAASLD: Pioneer who ‘propelled field of MASH forward’

Col. Stephen A. Harrison, MD, FAASLD, a key leader in the field of hepatology who dedicated his life to caring for patients and developing treatments for liver disease, died on April 23.

View more